For its day-to-day operations, Crucell has established a Management Committee that is also responsible for the design, implementation and management of long- and short-term strategy under the final responsibility of the Management Board.

Dr. Ronald Brus is Crucell’s President and Chief Executive Officer. He has been a member of Crucell’s Management Committee since the Company’s incorporation and was formerly Chief Operating Officer (March 2003 to January 2004) and Chief Business Officer (October 2000 to February 2003). Prior to that, he was Executive Vice President Business Development after joining the Company in 1997. From 1994 to 1996 he was product planning physician at Forest Laboratories in New York and from 1990 to 1994 he was Medical Director for Zambon B.V. He holds a medical degree from the University of Groningen, the Netherlands.

• Dr Brus is Chairman of the Management Board.

Mr. Kruimer has been Chief Financial Officer, since he joined Crucell in 1998. He became a member of Crucell’s Management Board in January 2005. Prior to that, he was a consultant at Pepsico and Royal Boskalis Westminster. From 1993 to 1995, he was Managing Director Continental Europe at GE Capital/TIP Europe. He also held senior executive positions at Kwik-Fit Europe and Continental Can Europe; and was a consultant with McKinsey & Co. He started his career at PriceWaterhouse in New York. He holds an MBA from the Harvard Graduate School of Business and an undergraduate degree from the University of Massachusetts. He is a CPA in New York State.

• Mr Kruimer is a member of the Management Board.

Dr. Cees de Jong joined Crucell as Chief Operating Officer in September 2007, after working at Quest International in Naarden, the Netherlands, as a member of the Board responsible for the Flavours Division. Prior to Quest, he worked as Managing Director of DSM Anti-infectives. In 1989 he started his career at Gist Brocades, holding a variety of roles in Business Development, Strategy and General Management before the company’s acquisition by DSM in 1998. He holds a medical degree and earned an MBA at the Erasmus University, Rotterdam, the Netherlands.

• Dr De Jong is a member of the Management Board.

Dr. Jaap Goudsmit is Crucell’s Chief Scientific Officer and is responsible for all R&D activities. He became a member of Crucell’s Management Board in January 2004. He joined Crucell in 2001 as Senior Vice President Vaccine Research and became a member of Crucell’s Management Committee in July 2002. Prior to that, he held various positions at the Academic Medical Center at the University of Amsterdam and was Chairman of the Research Institute for Infectious Diseases and the Institute for Science Education. Since 1989 he has been a professor at the University of Amsterdam and the Academic Medical Center. He holds a medical degree and a PhD from the University of Amsterdam, the Netherlands.

• Dr Goudsmit is a member of the Management Board.

Mr. Beukema is Crucell’s General Counsel and Corporate Secretary since the Company’s incorporation. He held the same position at IntroGene after joining the company in 1999. From 1994 to 1999, he was Senior Legal Counsel for GE Capital/TIP Europe. From 1991 to 1994, he was Legal Counsel for TNT Express Worldwide N.V. He has a Masters in Law from the University of Amsterdam, the Netherlands.

Mr. Arthur Lahr is Crucell’s Chief Strategy Officer and Executive Vice President Business Development. He joined Crucell in April 2001 as Executive Director Business Development and became a member of the Management Committee in January 2004, Executive Vice President in January 2006 and assumed responsibility for European marketing & sales and company strategy in 2006. From 1994 to 2001 he was a consultant with McKinsey & Co. in the Netherlands and New York. Prior to that, he worked at Unilever. He holds a Masters in Business Administration from INSEAD and a Masters in Science in Applied Physics from the University of Delft, the Netherlands.

Mr. Björn Sjöstrand is Chief Business Officer and a member of Crucell’s Management Committee. He was Chief Executive Officer at SBL Vaccines before it was acquired by Crucell in November 2006. He headed the Crucell-SBL integration committee and directed the travel franchise and the Nordic sales force for the Crucell Group. Prior to that, he worked as Vice President Operations & IT at Active Biotech and was a member of the Senior Management Team. He completed a Bachelor of Science degree in Economics and Business Administration at the University of Örebro, Sweden. He also studied Financial Investment theory and Commercial law at the same university.